Literature DB >> 24150219

Use of the 46/1 haplotype to model JAK2(V617F) clonal architecture in PV patients: clonal evolution and impact of IFNα treatment.

S Hasan1, B Cassinat2, N Droin1, J P Le Couedic1, F Favale1, B Monte-Mor1, C Lacout1, M Fontenay3, C Dosquet2, C Chomienne4, E Solary1, J L Villeval1, N Casadevall5, J J Kiladjian6, W Vainchenker1, I Plo1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24150219     DOI： 10.1038/leu.2013.303

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  15 in total

Review 1.  A JAK2 mutation in myeloproliferative disorders: pathogenesis and therapeutic and scientific prospects.

Authors:  Chloé James; Valérie Ugo; Nicole Casadevall; Stefan N Constantinescu; William Vainchenker
Journal:  Trends Mol Med       Date:  2005-11-03       Impact factor: 11.951

2.  The JAK2 617V>F mutation triggers erythropoietin hypersensitivity and terminal erythroid amplification in primary cells from patients with polycythemia vera.

Authors:  Sabrina Dupont; Aline Massé; Chloé James; Irène Teyssandier; Yann Lécluse; Frédéric Larbret; Valérie Ugo; Patrick Saulnier; Serge Koscielny; Jean Pierre Le Couédic; Nicole Casadevall; William Vainchenker; François Delhommeau
Journal:  Blood       Date:  2007-03-27       Impact factor: 22.113

3.  A common JAK2 haplotype confers susceptibility to myeloproliferative neoplasms.

Authors:  Damla Olcaydu; Ashot Harutyunyan; Roland Jäger; Tiina Berg; Bettina Gisslinger; Ingrid Pabinger; Heinz Gisslinger; Robert Kralovics
Journal:  Nat Genet       Date:  2009-03-15       Impact factor: 38.330

4.  Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference.

Authors:  Giovanni Barosi; Gunnar Birgegard; Guido Finazzi; Martin Griesshammer; Claire Harrison; Hans Carl Hasselbalch; Jean-Jacques Kiladjian; Eva Lengfelder; Mary Frances McMullin; Francesco Passamonti; John T Reilly; Alessandro M Vannucchi; Tiziano Barbui
Journal:  Blood       Date:  2009-03-10       Impact factor: 22.113

5.  Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.

Authors:  Ross L Levine; Martha Wadleigh; Jan Cools; Benjamin L Ebert; Gerlinde Wernig; Brian J P Huntly; Titus J Boggon; Iwona Wlodarska; Jennifer J Clark; Sandra Moore; Jennifer Adelsperger; Sumin Koo; Jeffrey C Lee; Stacey Gabriel; Thomas Mercher; Alan D'Andrea; Stefan Fröhling; Konstanze Döhner; Peter Marynen; Peter Vandenberghe; Ruben A Mesa; Ayalew Tefferi; James D Griffin; Michael J Eck; William R Sellers; Matthew Meyerson; Todd R Golub; Stephanie J Lee; D Gary Gilliland
Journal:  Cancer Cell       Date:  2005-04       Impact factor: 31.743

6.  Conditional expression of heterozygous or homozygous Jak2V617F from its endogenous promoter induces a polycythemia vera-like disease.

Authors:  Hajime Akada; Dongqing Yan; Haiying Zou; Steven Fiering; Robert E Hutchison; M Golam Mohi
Journal:  Blood       Date:  2010-03-02       Impact factor: 22.113

7.  Interferon-alpha targets JAK2V617F-positive hematopoietic progenitor cells and acts through the p38 MAPK pathway.

Authors:  Min Lu; Wei Zhang; Yan Li; Dmitriy Berenzon; Xiaoli Wang; Jiapeng Wang; John Mascarenhas; Mingjiang Xu; Ronald Hoffman
Journal:  Exp Hematol       Date:  2010-03-18       Impact factor: 3.084

8.  A gain-of-function mutation of JAK2 in myeloproliferative disorders.

Authors:  Robert Kralovics; Francesco Passamonti; Andreas S Buser; Soon-Siong Teo; Ralph Tiedt; Jakob R Passweg; Andre Tichelli; Mario Cazzola; Radek C Skoda
Journal:  N Engl J Med       Date:  2005-04-28       Impact factor: 91.245

9.  A germline JAK2 SNP is associated with predisposition to the development of JAK2(V617F)-positive myeloproliferative neoplasms.

Authors:  Outi Kilpivaara; Semanti Mukherjee; Alison M Schram; Martha Wadleigh; Ann Mullally; Benjamin L Ebert; Adam Bass; Sachie Marubayashi; Adriana Heguy; Guillermo Garcia-Manero; Hagop Kantarjian; Kenneth Offit; Richard M Stone; D Gary Gilliland; Robert J Klein; Ross L Levine
Journal:  Nat Genet       Date:  2009-03-15       Impact factor: 38.330

10.  Effects of the JAK2 mutation on the hematopoietic stem and progenitor compartment in human myeloproliferative neoplasms.

Authors:  Shubha Anand; Frances Stedham; Philip Beer; Emma Gudgin; Christina A Ortmann; Anthony Bench; Wendy Erber; Anthony R Green; Brian J P Huntly
Journal:  Blood       Date:  2011-05-11       Impact factor: 22.113
View more
  6 in total

1.  p53 at the crossroads of MPN treatment.

Authors:  Isabelle Plo
Journal:  Blood       Date:  2014-07-31       Impact factor: 22.113

2.  Inferring the dynamics of mutated hematopoietic stem and progenitor cells induced by IFNα in myeloproliferative neoplasms.

Authors:  Matthieu Mosca; Gurvan Hermange; Amandine Tisserand; Robert Noble; Christophe Marzac; Caroline Marty; Cécile Le Sueur; Hugo Campario; Gaëlle Vertenoeil; Mira El-Khoury; Cyril Catelain; Philippe Rameau; Cyril Gella; Julien Lenglet; Nicole Casadevall; Rémi Favier; Eric Solary; Bruno Cassinat; Jean-Jacques Kiladjian; Stefan N Constantinescu; Florence Pasquier; Michael E Hochberg; Hana Raslova; Jean-Luc Villeval; François Girodon; William Vainchenker; Paul-Henry Cournède; Isabelle Plo
Journal:  Blood       Date:  2021-12-02       Impact factor: 22.113

Review 3.  Interferon-alpha for the therapy of myeloproliferative neoplasms: targeting the malignant clone.

Authors:  J-J Kiladjian; S Giraudier; B Cassinat
Journal:  Leukemia       Date:  2015-11-25       Impact factor: 11.528

4.  Molecular responses and chromosomal aberrations in patients with polycythemia vera treated with peg-proline-interferon alpha-2b.

Authors:  Nicole C C Them; Klaudia Bagienski; Tiina Berg; Bettina Gisslinger; Martin Schalling; Doris Chen; Veronika Buxhofer-Ausch; Josef Thaler; Ernst Schloegl; Guenther A Gastl; Dominik Wolf; Karin Strecker; Alexander Egle; Thomas Melchardt; Sonja Burgstaller; Ella Willenbacher; Oleh Zagrijtschuk; Christoph Klade; Richard Greil; Heinz Gisslinger; Robert Kralovics
Journal:  Am J Hematol       Date:  2015-03-02       Impact factor: 10.047

5.  Ropeginterferon alpha-2b targets JAK2V617F-positive polycythemia vera cells in vitro and in vivo.

Authors:  Emmanuelle Verger; Juliette Soret-Dulphy; Nabih Maslah; Lydia Roy; Jerome Rey; Zineb Ghrieb; Robert Kralovics; Heinz Gisslinger; Barbara Grohmann-Izay; Christoph Klade; Christine Chomienne; Stéphane Giraudier; Bruno Cassinat; Jean-Jacques Kiladjian
Journal:  Blood Cancer J       Date:  2018-10-04       Impact factor: 11.037

Review 6.  Next Generation Sequencing in MPNs. Lessons from the Past and Prospects for Use as Predictors of Prognosis and Treatment Responses.

Authors:  Vibe Skov
Journal:  Cancers (Basel)       Date:  2020-08-06       Impact factor: 6.639
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.